Alixorexton

Last updated

Alixorexton
Alixorexton.svg
Clinical data
Other namesALKS-2680; ALKS2680
Routes of
administration 		Oral
Drug class Orexin OX2 receptor agonist
Identifiers
  • N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
Formula C21H30N2O5S
Molar mass 422.54 g·mol−1
3D model (JSmol)
  • O=C1N2CCC[C@@H]([C@@H]2CO[C@@H]3CC[C@@H](CC3)C4=C(OC1)C=CC=C4)NS(=O)(C)=O
  • InChI=InChI=1S/C21H30N2O5S/c1-29(25,26)22-18-6-4-12-23-19(18)13-27-16-10-8-15(9-11-16)17-5-2-3-7-20(17)28-14-21(23)24/h2-3,5,7,15-16,18-19,22H,4,6,8-14H2,1H3/t15?,16?,18-,19-/m0/s1
  • Key:IHNJMACFBQEKRJ-VHZYLWGESA-N

Alixorexton (INN Tooltip International Nonproprietary Name; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia. [1] [2] [3] Alixorexton is being developed by Alkermes [4] As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1. [4]

See also

References

  1. ↑ "Alixorexton - Alkermes". AdisInsight. Springer Nature Switzerland AG. Retrieved 2025-07-30.
  2. ↑ Morse AM (May 2025). "Enhancing the Management of Hypersomnia: Examining the Role of the Orexin System". Seminars in Neurology. 45 (3): 410–419. doi:10.1055/a-2589-3825. PMID   40239951.
  3. ↑ Prakash BA, Shah I, Ni G, Vasudevan S, Jagannath A, Foster RG (May 2025). "Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy". Journal of Sleep Research e70087. doi:10.1111/jsr.70087. PMID   40346938.
  4. 1 2 Chen E (2025-07-21). "Alkermes drug helped narcolepsy patients stay awake in Phase 2 trial". STAT. Retrieved 2025-07-30.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.